🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against superbug strains of the pathogen, according to researchers.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing around the world, with data suggesting more than 82 million infections per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Approval

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This approval marks a significant shift in the therapy of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

Based on data published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The study included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the authority to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have shared positive views. Access to a single-dose, oral treatment of this kind is described as a "critical tool" for public health efforts. This is viewed as essential to reduce the burden of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.